Publication | Open Access

Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial

UrologyPatient-reported OutcomesMedicineClinical TrialsOutcomes ResearchPatient-reported OutcomePharmacotherapyCastration-resistant Prostate CancerProstatic DiseaseDrug TrialOncology